Allogene Therapeutics To Lay Off 22% Of Its Workforce; Stock Down
Gene editing company, Allogene Therapeutics, Inc. (ALLO), Friday announced its decision to cut down its workforce by 22% in a move to focus on developing its blood cancer therapy.
Source: rttnews.com